![](/img/cover-not-exists.png)
PCN93 COST-MINIMIZATION ANALYSIS OF XELOX (CAPECITABINE + OXALIPLATIN) VERSUS FOLFOX-4 (5-FU/LV + OXALIPLATIN) AS ADJUVANT TREATMENT IN STAGE III COLON CANCER UNDER THE BRAZILIAN PRIVATE PAYER PERSPECTIVE
G Prolla, LG Borges, E SantosVolume:
13
Year:
2010
Language:
english
DOI:
10.1016/s1098-3015(11)71988-x
File:
PDF, 99 KB
english, 2010